The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Peptide-based therapy in portal hypertension
Mohanty A1. Curr Opin Endocrinol Diabetes Obes. 2019 Dec 6. doi: 10.1097/MED.0000000000000528. [Epub ahead of print]
Author information
1 Boston University School of Medicine, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: To summarize the use of gastrointestinal peptides in the management of portal hypertension.
RECENT FINDINGS: Vasoactive peptides are commonly used in the management of acute variceal hemorrhage and hepatorenal syndrome, which are portal hypertensive complications of cirrhosis. The main vasoactive peptides that are used are somatostatin and its long-acting analogue octreotide, and vasopressin and its analogue terlipressin. Early initiation of vasoactive peptides in the management of acute variceal hemorrhage and hepatorenal syndrome is associated with improved outcomes. Octreotide is the available vasoactive peptide in the Unites States. Recent developments and ongoing clinical trials may improve our understanding of hepatorenal syndromeand influence the use of vasoactive peptides, particularly terlipressin.
SUMMARY: Here, we review the literature on the use of vasoactive peptides in the management of acute variceal hemorrhage and hepatorenal syndrome.